Discover
HELP
Cybin D/B/A Helus Pharma
11.80
2 x 6.79
2 x 11.87
bid
ask
+
1.08
10.07%
2 @ 07:59 PM
11.95 +0.15 (1.27%)
| Ytd | 44.25% | |
| 1y | 88.20% |
10.45
day range
12.09
3.87
52 week range
14.02
| Open | 10.71 | Prev Close | 10.72 | Low | 10.45 | High | 12.09 | Mkt Cap | 862.22M |
| Vol | 1.66M | Avg Vol | 1.77M | EPS | -4.15 | P/E | N/A | Forward P/E | -7.55 |
| Beta | 0.63 | Short Ratio | 1.59 | Inst. Own | 41.29% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 11.91 | 200-d Avg | 7.49 | 1yr Est | 40.24 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-12 | 2026-09 | -0.67 | N/A | N/A | N/A |
| 2026-08-14 | 2026-06 | -0.84 | -0.91 | -0.07 | -8.84% |
| 2026-06-30 | 2026-03 | -1.04 | -0.96 | 0.08 | 8.09% |
| 2026-02-13 | 2025-12 | -0.53 | -0.99 | -0.46 | -87.25% |
| 2025-11-13 | 2025-09 | -0.74 | -1.39 | -0.65 | -87.84% |
| 2025-08-13 | 2025-06 | -0.96 | -1.1 | -0.14 | -14.72% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-09-18 | Barclays | Upgrade | Overweight | |
| 2026-08-20 | TD Cowen | Upgrade | Buy | Buy |
| 2026-07-27 | Wells Fargo | Upgrade | Overweight | |
| 2026-07-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-07-01 | Canaccord Genuity | Upgrade | Buy | Buy |
| 2026-04-13 | TD Cowen | Upgrade | Buy |
Profile
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-09-01 | Bartlone (Aaron Frank) | Senior Officer of Issuer | 225.15K | Acquisition or disposition in the public market |
| 2026-09-01 | Cavers (Gregory Joseph) | Senior Officer of Issuer | 125.94K | Acquisition or disposition in the public market |
| 2026-09-14 | Fahel (Gabriel) | Senior Officer of Issuer | 102.96K | Acquisition or disposition in the public market |
| 2026-08-31 | Froese (Grant B.) | Director of Issuer | 0.00 | Exercise of rights |
| 2026-09-07 | Glavine (Paul) | Director of Issuer | 4.25M | Acquisition or disposition in the public market |
| 2026-08-31 | Hoskins (Eric William) | Director of Issuer | 0.00 | Exercise of rights |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Venrock Adviser, LLC | 3.85M | 52.81M | 4.89% |
| 2026-06-29 | Orbimed Advisors LLC. | 3.27M | 44.85M | 4.16% |
| 2026-06-29 | Adage Capital Partners GP L.L.C. | 3.06M | 41.95M | 3.89% |
| 2026-06-29 | Millennium Management Llc | 2.63M | 36.09M | 3.34% |
| 2026-06-29 | Rosalind Advisors, Inc. | 1.96M | 26.83M | 2.49% |
| 2026-06-29 | Sphera Funds Management Ltd. | 1.62M | 22.22M | 2.06% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-08-30 | AdvisorShares Trust-AdvisorShares Psychedelics ETF | 367.43K | 5.04M | 0.47% |
| 2026-06-29 | ROYCE FUND-Royce Smaller-Companies Growth Fund | 232.00K | 3.18M | 0.29% |
| 2026-07-30 | Invesco Exch-Trd Fd. TRT II-Invesco NASDAQ Future Gen 200 ETF | 24.58K | 336.94K | 0.03% |
| 2026-07-30 | Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 15.99K | 219.24K | 0.02% |
| 2026-06-29 | TIFF INVESTMENT PROGRAM-TIFF Multi-Asset Fund | 1.80K | 24.73K | 0.00% |